174 related articles for article (PubMed ID: 15865440)
1. Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes.
Zhang J; Osslund TD; Plant MH; Clogston CL; Nybo RE; Xiong F; Delaney JM; Jordan SR
Biochemistry; 2005 May; 44(18):6948-57. PubMed ID: 15865440
[TBL] [Abstract][Full Text] [Related]
2. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
3. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
4. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
6. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
9. 17Beta-estradiol inhibits 11beta-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes.
Tagawa N; Yuda R; Kubota S; Wakabayashi M; Yamaguchi Y; Kiyonaga D; Mori N; Minamitani E; Masuzaki H; Kobayashi Y
J Endocrinol; 2009 Jul; 202(1):131-9. PubMed ID: 19380458
[TBL] [Abstract][Full Text] [Related]
10. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
11. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1.
Balázs Z; Nashev LG; Chandsawangbhuwana C; Baker ME; Odermatt A
Mol Cell Endocrinol; 2009 Mar; 301(1-2):117-22. PubMed ID: 19010388
[TBL] [Abstract][Full Text] [Related]
12. Mouse 17alpha-hydroxysteroid dehydrogenase (AKR1C21) binds steroids differently from other aldo-keto reductases: identification and characterization of amino acid residues critical for substrate binding.
Faucher F; Cantin L; Pereira de Jésus-Tran K; Lemieux M; Luu-The V; Labrie F; Breton R
J Mol Biol; 2007 Jun; 369(2):525-40. PubMed ID: 17442338
[TBL] [Abstract][Full Text] [Related]
13. The selectivity of tyrosine 280 of human 11beta-hydroxysteroid dehydrogenase type 1 in inhibitor binding.
Kim KW; Wang Z; Busby J; Tsuruda T; Chen M; Hale C; Castro VM; Svensson S; Nybo R; Xiong F; Wang M
FEBS Lett; 2007 Mar; 581(5):995-9. PubMed ID: 17306259
[TBL] [Abstract][Full Text] [Related]
14. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.
Chapman KE; Coutinho A; Gray M; Gilmour JS; Savill JS; Seckl JR
Ann N Y Acad Sci; 2006 Nov; 1088():265-73. PubMed ID: 17192572
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
16. The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
Odermatt A; Nashev LG
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):1-13. PubMed ID: 20100573
[TBL] [Abstract][Full Text] [Related]
17. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
18. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Blum A; Favia AD; Maser E
Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
[TBL] [Abstract][Full Text] [Related]
19. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
20. Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis.
Liu Y; Park F; Pietrusz JL; Jia G; Singh RJ; Netzel BC; Liang M
Physiol Genomics; 2008 Feb; 32(3):343-51. PubMed ID: 18073273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]